ESC Premium Access

Dual antithrombotic therapy is similarly effective to triple therapy in preventing thrombotic events in patients with atrial fibrillation and acute coronary syndrome

Congress Presentation

About the speaker

Professor Zuzana Motovska

Third Faculty of Medicine, Charles University and University Hospital Kralovske Vinohrady, Prague (Czechia)
1 presentation
0 follower

8 more presentations in this session

Direct comparison of dabigatran, apixaban, rivaroxaban and edoxaban for effectiveness and safety among patients with non-valvular atrial fibrillation

Speaker: Doctor E. Choi (Seoul, KR)


Treatment persistence of patients with atrial fibrillation on VKA or NOAC: Data from GLORIA-AF Phase III 1-year interim analysis

Speaker: Professor G. Lip (Liverpool, GB)


Efficacy and safety of dronedarone by duration of atrial fibrillation history: a post-hoc analysis of the ATHENA trial

Speaker: Professor C. Blomstrom-Lundqvist (Orebro, SE)


Clinical characteristics and 1-year outcomes in atrial fibrillation patients with or without history of intracranial haemorrhage treated with edoxaban: snapshot analysis of the Global ETNA-AF program

Speaker: Professor P. Kirchhof (Hamburg, DE)


Use of direct oral anticoagulants in patients with atrial fibrillation having a history of intracranial hemorrhage

Speaker: Doctor T. Chao (Taipei, TW)


Access the full session

Poster Session 5 - Atrial fibrillation and oral anticoagulation 5

Speakers: Professor Z. Motovska, Doctor E. Choi, Professor G. Lip, Professor C. Blomstrom-Lundqvist, Professor P. Kirchhof...

About the event


ESC Congress 2019

31 August - 4 September 2019

Sessions Presentations

ESC 365 is supported by

logo Novo Nordisk
logo Bristol Myers Squibb